Difference between revisions of "CT Angiography Biomarker Ctte"
m (→Meetings) |
|||
Line 34: | Line 34: | ||
==Profile Development== | ==Profile Development== | ||
+ | * [[Media:QIBA CTA Profile as of 2020-Mar-10.pdf|CTA Atherosclerosis 2020-03-10]] | ||
+ | * [[Media:QIBA CTA Field Test Checklist.xlsx|Checklists - CTA Atherosclerosis 2020-05-28]] | ||
*[[Media:Atherosclerosis Biomarkers Profile 2019-11-27-full.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | *[[Media:Atherosclerosis Biomarkers Profile 2019-11-27-full.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] | ||
*[[Media:Atherosclerosis Biomarkers Profile 2019-11-27.PDF| QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)]] | *[[Media:Atherosclerosis Biomarkers Profile 2019-11-27.PDF| QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)]] |
Revision as of 17:10, 29 March 2023
Co-chairs: Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
RSNA Staff Support: Julie Lisiecki
Meetings
Recent Call Summaries:
- March 14, 2023
- February 14, 2023
- January 24, 2023
- January 10, 2023
- December 6, 2022
- October 25, 2022
- October 11, 2022
- September 27, 2022
- September 13, 2022
- August 30, 2022
- August 16, 2022
- June 16, 2020
CT Angiography Call Summaries Archive
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
Profile Development
- CTA Atherosclerosis 2020-03-10
- Checklists - CTA Atherosclerosis 2020-05-28
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
Atherosclerosis Biomarkers Profile Draft Archive
Groundwork Projects
Reference Materials
- QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler} March 27, 2018 (PDF)